Was med-tech startup, Theranos, following in the footsteps of Uber and simply embarking on “permissionless” innovation? Or is its current firestorm the consequence of groupthink given its storied roster of investors and board members? With $400M in investments and a $9B valuation, MPD CEO Karen Webster says more likely the latter than the former. She lays out the case, and more importantly, the dangers for payments when groupthink trumps healthy debate over the merits of an innovation and its true potential.